CoChat

Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study

Open access
Tan, Ban Hock, Low, Jenny Guek Hong, Chlebicka, Nidhi L., Kurup, Asok, Cheah, Foong Koon, Lin, Raymond Tzer Pin, Goh, Yeow Tee, Wong, Gee Chuan · 2011 · International Journal of Infectious Diseases
Cited by 58

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Patients with neutropenic fever after 4-7 days of broad-spectrum antibiotics are given antifungals empirically. This strategy may lead to over-treatment. METHODS: Patients with hematological malignancies undergoing intensive chemotherapy or hematopoietic stem cell transplantation were randomized to two arms. Patients in the 'preemptive' arm had regular galactomannan (GM) assays, and received caspofungin, amphotericin or voriconazole (CAV) for persistent febrile neutropenia if they had two positive GM results, or a positive GM result and a computed tomography (CT) of the thorax suggestive of invasive pulmonary aspergillosis (IPA). Patients in the 'empirical' arm received CAV in accordance with established guidelines. RESULTS: Of 27 episodes in the preemptive arm, two cases of IPA were picked up by monitoring. In six episodes, CAV was started despite persistently negative GM readings. One additional patient received CAV for a false-positive GM. Of 25 episodes in the empirical arm, CAV was started empirically in 10, one of whom had CT features of IPA. By intent-to-treat and evaluable-episode analyses, respectively, the preemptive approach saved 11% and 14% of patients from empirical antifungals. Twelve-week survival was 85.2% in the preemptive arm and 84% in the empirical arm. CONCLUSIONS: A preemptive approach may reduce empirical antifungal use without compromising survival in persistently febrile neutropenic patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ijid.2011.01.011

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 24

  1. Marr, 2002, Empirical antifungal therapy—new options, new tradeoffs, N Engl J Med, 346, 278, 10.1056/NEJM200201243460410 · DOI
  2. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668–72. · DOI · Paper page
  3. Rieger, 2008, Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients, Mycoses, 51, 31, 10.1111/j.1439-0507.2008.01526.x · DOI
  4. Maertens, 2005, Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study, Clin Infect Dis, 41, 1242, 10.1086/496927 · DOI · Paper page
  5. de Pauw, 2009, Between over- and undertreatment of invasive fungal disease, Clin Infect Dis, 45, 1251
  6. Kalil, 2005, Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients, Ann Intern Med, 143, 870, 10.7326/0003-4819-143-12-200512200-00005 · DOI · Paper page
  7. Jones, 2003, Impact of diagnostic markers on early antifungal therapy, Curr Opin Infect Dis, 16, 521, 10.1097/00001432-200312000-00002 · DOI
  8. Herbrecht, 2008, Beta-d-glucan detection test: a step towards preemptive therapy for fungal infections in leukemic patients?, Clin Infect Dis, 46, 886, 10.1086/527383 · DOI
  9. Wong, 2008, Use of antibiotics in a haematology ward—an audit, Ann Acad Med Singapore, 37, 21, 10.47102/annals-acadmedsg.V37N1p21 · doi:10.47102/annals-acadmedsg.v37n1p21
  10. Ascioglu, 2002, Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus, Clin Infect Dis, 34, 7, 10.1086/323335 · DOI · Paper page
  11. Maertens, 2008, Early diagnosis and preemptive therapy of pulmonary mold infections in high-risk patients, Curr Infect Dis Rep, 10, 459, 10.1007/s11908-008-0075-y · DOI
  12. Cordonnier, 2009, Empirical and preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial, Clin Infect Dis, 48, 1042, 10.1086/597395 · DOI · Paper page
  13. Oshima, 2007, Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients, J Antimicrob Chemother, 60, 350, 10.1093/jac/dkm217 · DOI
  14. Singh, 2001, Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients, Clin Infect Dis, 32, 742, 10.1086/319225 · DOI
  15. Konstantinos, 2005, Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials, Br J Haematol, 131, 22, 10.1111/j.1365-2141.2005.05727.x · DOI · Paper page
  16. Koh, 2002, Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation, Am J Hematol, 71, 260, 10.1002/ajh.10234 · DOI
  17. Glasmacher, 2006, An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia, J Antimicrob Chemother, 57, 317, 10.1093/jac/dki440 · DOI · Paper page
  18. Paya, 2002, Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant recipients: a randomized, placebo-controlled trial, J Infect Dis, 185, 854, 10.1086/339449 · DOI
  19. Tan, 2008, Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world view, Transpl Infect Dis, 10, 325, 10.1111/j.1399-3062.2008.00325.x · doi:10.1111/j.1399-3062.2008.00325.x
  20. Pfeiffer, 2006, Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis, Clin Infect Dis, 24, 1414
  21. Marr, 2005, Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay, Clin Infect Dis, 40, 1762, 10.1086/429921 · DOI · Paper page
  22. Herbrecht, 2002, Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients, J Clin Oncol, 20, 1898, 10.1200/JCO.2002.07.004 · DOI · Paper page
  23. Siemann, 2001, The Platelia Aspergillus ELISA in diagnosis of invasive pulmonary aspergillosis (IPA), Mycoses, 44, 266
  24. Ruping, 2008, Patients at high risk of invasive fungal infections, Drugs, 68, 1941, 10.2165/00003495-200868140-00002 · DOI · Paper page

Cited by

Metadata

Authors
Tan, B. H., Low, J. G. H., Chlebicka, N. L., Kurup, A., Cheah, F. K., Lin, R. T. P., Goh, Y. T., & Wong, G. C.
Venue
International Journal of Infectious Diseases
Publisher
Elsevier BV
Published
2011-05
Volume
15
Issue
5
Pages
e350-e356
ISSN
1201-9712 (ISSN-L)
OpenAlex
W2012552495
Cited by
58
References
5
FWCI
3.40
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.